Clinical features of patients treated with alemtuzumab
Characteristic . | Patients . |
|---|---|
| Median age, y (range) | 61 (47-74) |
| No. men (%) | 29 (81) |
| Rai stage, no. (%) | |
| Intermediate risk | 9 (25) |
| High risk | 27 (75) |
| Median no. prior therapies (range) | 3 (1-12) |
| No. fludarabine refractory (%) | 29 (81) |
| Nonprioritization, no. (%) | |
| p53 mutation | 11 (31) |
| Patients with del(17)(p13.1) | 12 (33) |
| Patients with del(11)(q22.3) | 16 (44) |
| Patients with trisomy 12 | 3 (8) |
| Patients with del(13)(q14) | 23 (64) |
| Patients with del(6)(q21) | 4 (11) |
| Patients with normal interphase cytogenetics | 3 (8) |
| Prioritization, no. (%)* | |
| Patients with p53 mutation/del(17)(p13.1) | 15 (42) |
| Patients with del(11)(q22.3) | 11 (31) |
| Patients with trisomy 12 | 3 (8) |
| Patients with del(13)(q14) | 4 (11) |
| Patients with normal interphase cytogenetics | 3 (8) |
Characteristic . | Patients . |
|---|---|
| Median age, y (range) | 61 (47-74) |
| No. men (%) | 29 (81) |
| Rai stage, no. (%) | |
| Intermediate risk | 9 (25) |
| High risk | 27 (75) |
| Median no. prior therapies (range) | 3 (1-12) |
| No. fludarabine refractory (%) | 29 (81) |
| Nonprioritization, no. (%) | |
| p53 mutation | 11 (31) |
| Patients with del(17)(p13.1) | 12 (33) |
| Patients with del(11)(q22.3) | 16 (44) |
| Patients with trisomy 12 | 3 (8) |
| Patients with del(13)(q14) | 23 (64) |
| Patients with del(6)(q21) | 4 (11) |
| Patients with normal interphase cytogenetics | 3 (8) |
| Prioritization, no. (%)* | |
| Patients with p53 mutation/del(17)(p13.1) | 15 (42) |
| Patients with del(11)(q22.3) | 11 (31) |
| Patients with trisomy 12 | 3 (8) |
| Patients with del(13)(q14) | 4 (11) |
| Patients with normal interphase cytogenetics | 3 (8) |
Prioritization performed as follows: del(17)(p13.1) or p53 mutation > del(11)(q22.3) > trisomy 12 > del(13)(q14) > normal.